2 citations
,
January 2021 in “Turkiye Klinikleri Journal of Internal Medicine” This study outlines the temporary or sometimes permanent hair loss caused by cancer treatments, noting it often starts 2-3 weeks after chemotherapy and highlights the need for more research into prevention and treatment strategies for therapy-related alopecia.
52 citations
,
May 2013 in “Supportive Care in Cancer” Scalp cooling significantly reduces hair loss in chemotherapy patients.
March 2024 in “Research Square (Research Square)” In this study, scalp cooling therapy was found to be well tolerated and effective at improving hair preservation for Asian women with breast or gynecological cancers undergoing certain chemotherapy regimens, particularly weekly paclitaxel, compared to historical controls.
3 citations
,
November 2018 in “Oncology issues” This article discusses the emerging field of supportive oncodermatology, which collaborates between oncology and dermatology to address skin-related side effects of cancer treatments, and reports no new clinical results.
June 2026 in “Pathology & Oncology Research” In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.
